Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 8/20 | 0.51 |
| ▸ | MMP2 | P08253 | 7/20 | 0.51 |
| ▸ | MMP3 | P08254 | 4/20 | 0.51 |
| ▸ | MMP13 | P45452 | 2/20 | 0.49 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | SCN1A | P35498 | 1/20 | 0.43 |
| ▸ | SCN4A | P35499 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.43 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.43 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.43 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Allobarbital SCHEMBL3642549 | 0.94 | MMP2 (0.47) | MMP9MMP2MMP3MMP13CACNA1F | |
| Phenobarbital SCHEMBL7618451 | 0.92 | MMP9 (0.63) | MMP9MMP2MMP3MMP13LMNA | |
| SCHEMBL32689845 | 0.87 | KMT2A (0.42) | MMP9MMP2MMP3MMP13CACNA1F | |
| SCHEMBL11278266 | 0.84 | MMP9 (0.53) | MMP9MMP2MMP3MMP13CACNA1F | |
| SCHEMBL23959035 | 0.80 | LMNA (0.51) | MMP9MMP2MMP3KCNH2LMNA | |
| SCHEMBL11406274 | 0.77 | MMP9 (0.50) | MMP9MMP2MMP3MMP13CACNA1F | |
| SCHEMBL4384790 | 0.77 | GABRA1 (0.40) | MMP9MMP2MMP3MMP13MAPT | |
| Phenobarbital SCHEMBL22719965 | 0.76 | MMP2 (0.75) | MMP9MMP2MMP3MMP13CACNA1F | |
| Phenobarbital SCHEMBL18222943 | 0.76 | MMP9 (0.63) | MMP9MMP2MMP3MMP13LMNA | |
| Phenobarbital SCHEMBL16583 | 0.76 | MMP2 (0.80) | MMP9MMP2MMP3MMP13CACNA1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 727 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260041939-A1 | METHODS FOR THE TREATMENT OF HYPERTENSION VIA TRANSCRANIAL-FOCUSED-ULTRASOUND | SUNNYBROOK RES INST (CA) | 2026-02-12 | — | — | US | claimed |
| US-12161695-B2 | GABA A receptor agonists for treatment of disorders influenced by dysfunction BETA cells | DIAMYD MEDICAL AB (SE) | 2024-12-10 | — | — | US | claimed |
| US-11839615-B2 | Compounds and methods for treating addiction and related disorders | ASTROCYTE PHARMACEUTICALS, INC. (US) | 2023-12-12 | — | — | US | claimed |
| US-20210113586-A1 | NEW USE AND METHODS OF MODULATING IMMUNE RESPONSES | DIAMYD MEDICAL AB (SE) | 2021-04-22 | — | — | US | claimed |
| US-20210030760-A1 | COMPOUNDS AND METHODS FOR TREATING ADDICTION AND RELATED DISORDERS | ASTROCYTE PHARMACEUTICALS, INC. | 2021-02-04 | — | — | US | claimed |
| EP-3756007-A1 | NEW USE AND METHODS OF MODULATING IMMUNE RESPONSES | Diamyd Medical AB (SE) | 2020-12-30 | — | — | EP | claimed |
| EP-3755314-A1 | GABA A RECEPTOR AGONISTS FOR TREATMENT OF DISORDERS INFLUENCED BY DYSFUNCTION BETA CELLS | Diamyd Medical AB (SE) | 2020-12-30 | — | — | EP | claimed |
| EP-3749322-A1 | COMPOUNDS AND METHODS FOR TREATING ADDICTION AND RELATED DISORDERS | Astrocyte Pharmaceuticals, Inc. (US) | 2020-12-16 | — | — | EP | claimed |
| US-20200384086-A1 | GABA A RECEPTOR AGONISTS FOR TREATMENT OF DISORDERS INFLUENCED BY DYSFUNCTION BETA CELLS | DIAMYD MEDICAL AB (SE) | 2020-12-10 | — | — | US | claimed |
| US-20200138830-A1 | ENHANCING GABA'S ABILITY TO MODULATE IMMUNE RESPONSES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-05-07 | — | — | US | claimed |
| WO-2006127024-A1 | REAGENTS AND METHODS FOR LABELING TERMINAL OLEFINS | EISAI CO. LTD. (JP) | 2006-11-30 | — | — | WO | claimed |
| US-20060045846-A1 | Reagents and methods for labeling terminal olefins | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-03-02 | — | — | US | claimed |
| WO-2002006826-B1 | SINGLE-PATIENT DRUG TRIALS USED WITH ACCUMULATED DATABASE | OPT E SCRIP INC (US) | 2002-04-04 | — | — | WO | claimed |
| US-20020032581-A1 | Single-patient drug trials used with accumulated database: risk of habituation | OPT-E-SCRIP, INC. | 2002-03-14 | — | — | US | claimed |
| WO-2002006826-A1 | SINGLE-PATIENT DRUG TRIALS USED WITH ACCUMULATED DATABASE | OPT-E-SCRIP, INC. (US) | 2002-01-24 | — | — | WO | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| EP-1027609-A2 | METHOD FOR DETERMINATION OF DRUGS OF ABUSE IN BIOLOGICAL SAMPLES | Varian, Inc. (US) | 2000-08-16 | — | — | EP | claimed |
| WO-1999022244-A2 | METHOD FOR DETERMINATION OF DRUGS OF ABUSE IN BIOLOGICAL SAMPLES | VARIAN, INC. (US) | 1999-05-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11839615-B2 | Compounds and methods for treating addiction and related disorders | ADORA2A, TAAR5, ADORA3 | MMP9 4015/4885MMP2 3603/4885MMP3 2861/4885 |
| US-20260041939-A1 | METHODS FOR THE TREATMENT OF HYPERTENSION VIA TRANSCRANIAL-FOCUSED-ULTRASOUND | FABP7, FABP3, ADRB2 | MMP9 1199/4885MMP2 1438/4885MMP3 1651/4885 |
| US-20210030760-A1 | COMPOUNDS AND METHODS FOR TREATING ADDICTION AND RELATED DISORDERS | SLC6A3, PNMT, CES2 | MMP9 3124/4885MMP2 3280/4885MMP3 2446/4885 |
| US-20060045846-A1 | Reagents and methods for labeling terminal olefins | EEF2, RNF168, REL | MMP9 4827/4885MMP2 3808/4885MMP3 4219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.